JMP attends the PSI Conference in Edinburgh

Bernard McKeown
Bernard McKeown|April 30, 2013

I had the pleasure of interviewing Richard Zink, Principal Research Statistician Developer in the JMP Life Sciences division, prior to his visit to the UK to speak at the PSI (Statisticians in the Pharmaceutical Industry) Conference in Glasgow on 14 May. His PSI talk is titled “Assessing the Similarity of [...]

Post a Comment

Analyzing adverse events using Bayesian hierarchical models

Richard Zink
Richard Zink|April 26, 2013

You may be asking yourself… “Two Bayesian posts in a row? What is going on?” Though my statistical training focused on Frequentist methodologies, I am a big believer in using whatever tools help me gain insight into the statistical problem I happen to be focusing on at the moment. Frequentist [...]

The 2013 JMP Life Sciences European Roadshow

Richard Zink
Richard Zink|April 12, 2013

This May, JMP Life Sciences is going on the road in Europe to demo some of the new features that will be available in the upcoming releases of JMP Clinical 4.1 and JMP Genomics 6.1. The Roadshow is an excellent opportunity to hear about new functionality, ask questions or perhaps sneak [...]

Post a Comment

Truly efficient clinical reviews - no, we didn't forget the patient profiler

Richard Zink
Richard Zink|March 28, 2013

We’ve gotten some good feedback on our new review features that will become available in the upcoming JMP Clinical 4.1. If you’re new to the conversation, feel free to catch up here, here and here. The ability of JMP Clinical to identify new or modified data from snapshot to snapshot, [...]

Post a Comment

Truly efficient clinical reviews – an example

Richard Zink
Richard Zink|February 25, 2013

JMP Clinical 4.1 contains example data to help illustrate its new review functionality. This additional data is referred to as Nicardipine Early Snapshot, and includes Nicardipine data only through 01 Aug 1989. There are numerous changes to this data set: 11 subjects have yet to enroll in the trial, the [...]

Post a Comment

Truly efficient clinical reviews – it’s all about the keys

Richard Zink
Richard Zink|February 7, 2013

In last week’s post, we discussed some of the upcoming features of JMP Clinical 4.1 that identify new and modified records when clinical trial data is updated. These tools can greatly accelerate clinical reviews, allowing the clinician, statistician or data manager to focus exclusively on unreviewed records. Here we discuss [...]

Post a Comment

Truly efficient data reviews for clinical trials

Richard Zink
Richard Zink|January 28, 2013

Over the next few posts, I discuss the data review process for clinical trials and highlight some new features for JMP Clinical 4.1 that streamline this monumental endeavor. Ideally, the data from a clinical trial should be examined by as many eyes as possible – including data and protocol managers, [...]

Predictive modeling in the life sciences

Richard Zink
Richard Zink|January 18, 2013

This past week, Nate Silver held an “Ask Me Anything” chat on Reddit. There were several very good questions, one of which I found particularly important as we begin the International Year of Statistics: “What is the biggest abuse of statistics”? To which Nate replied: “Overfitting.” This response is very [...]

Post a Comment

Assessing the similarity of clinical trial subjects within study site

Richard Zink
Richard Zink|December 17, 2012

We’ve reached the end of our series of posts on fraud detection in clinical trials (for now, at least). Our final discussion focuses on the similarity of subjects within the clinical site, a topic that I hinted at in my response to a comment to one of my earlier posts. As part [...]

Post a Comment

Identifying multivariate inliers and outliers

Richard Zink
Richard Zink|December 10, 2012

We’re nearing the end of this series of posts on fraud detection in clinical trials and some upcoming features of JMP Clinical 4.1 that help identify unusual observations. We’ve described how visit dates and measurements taken in the clinic can signify problems at the clinical site, and discussed how trial [...]

Post a Comment